Last updated: April 17, 2026
What is HADLIMA?
HADLIMA (adalimumab-bwwd) is a biosimilar developed by Samsung Bioepis, approved by the U.S. Food and Drug Administration (FDA) in August 2021. It is a biosimilar to AbbVie's Humira (adalimumab), targeting multiple autoimmune conditions. The approved indications include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
How does HADLIMA compare to Humira in the biosimilar market?
HADLIMA enters a market controlled predominantly by Humira, which recorded global sales of approximately $21.4 billion in 2021. Biosimilar competition started gaining ground after patent expiration in the U.S. in January 2023. Multiple biosimilars, including Amgen's Amjevita, Sandoz’s Hyrimoz, and Eli Lilly’s yet-to-launch biosimilar, have sought market share.
Market Entry Timeline
| Year |
Key Event |
Details |
| 2016 |
Humira's patent expiry in Europe |
Allowed biosimilar entry |
| 2018 |
U.S. patent challenges |
Increased biosimilar preparations |
| 2021 |
HADLIMA approval |
First biosimilar approved for U.S. |
| 2023 |
Patents in U.S. begin to expire |
Market expansion for biosimilars |
| 2023 |
Multiple biosimilars launch in U.S. |
Competition intensifies |
What is the current market landscape?
The biosimilar market for adalimumab is expanding rapidly with increasing penetration. Key drivers include healthcare cost containment policies, physician acceptance, and payer reimbursement schemes.
Market Share and Sales Projections
| Biosimilar |
Market Share (Estimated, 2023) |
Revenue (Estimated, 2023) |
Price Discount vs. Humira |
| HADLIMA |
10-15% |
$1.0-$1.5 billion |
15-20% lower |
| Amjevita |
35-40% |
$4.5-$5.0 billion |
30-40% lower |
| Hyrimoz |
20-25% |
$2.0-$2.5 billion |
20-30% lower |
| Other biosimilars |
10-15% |
$0.7-$1.0 billion |
10-25% lower |
Source: IQVIA, 2023 estimates.
Cost Dynamics
Biosimilars such as HADLIMA reduce drug costs by approximately 15-20% compared to Humira. This pricing difference contributes to rapid adoption in payers and increasing market penetration.
What are the financial performance projections?
HADLIMA's sales are projected to grow as market share expands. Based on historical biosimilar trends, revenue growth may follow an S-curve pattern, with rapid uptake in the first 3–4 years post-launch.
Sales Forecast for HADLIMA (2023–2027)
| Year |
Estimated Revenue |
Notes |
| 2023 |
$1.0–$1.5 billion |
Initial market penetration |
| 2024 |
$2.0–$2.8 billion |
Growing adoption, wider payer coverage |
| 2025 |
$3.0–$4.2 billion |
Increased physician prescribing |
| 2026 |
$4.0–$5.5 billion |
Market stabilization, steady growth |
| 2027 |
$5.5–$7.0 billion |
Peak biosimilar adoption |
Profitability Outlook
Margins for biosimilars typically range between 15-25%. Samsung Bioepis's manufacturing efficiencies and competitive pricing contribute to sustainability. Pricing pressure from new entrants and continued patent litigations could temper margins post-2025.
What regulatory and policy factors influence HADLIMA's trajectory?
Regulatory pathways favor biosimilars with approved comparable efficacy and safety. The U.S. FDA’s increasing support for biosimilars, including incentivized formulary placement, supports market expansion.
Key Regulatory Milestones
- FDA approval in 2021
- Biologics Price Competition and Innovation Act (BPCIA) provisions enable biosimilar manufacturing and approval
- State-level mandates for biosimilar substitution in pharmacy benefit management
Policy Trends
- Payer efforts to negotiate lower drug prices
- State legislation encouraging biosimilar substitution
- Growing acceptance among physicians and consumers
What challenges and opportunities exist?
Challenges
- Patent litigations delaying biosimilar launches
- Physician and patient skepticism about biosimilar interchangeability
- Price competition from multiple biosimilars
Opportunities
- Early adoption in emerging markets
- Expansion into additional indications
- Development of next-generation biosimilars with enhanced features
What are the key takeaways?
- HADLIMA is competing in a rapidly evolving biosimilar landscape dominated by price reductions and increased market penetration
- Sales are projected to increase substantially between 2023 and 2027, reaching approximately $5.5 to $7.0 billion
- Price discounts of 15-20% versus Humira provide a competitive advantage but face pressure as more biosimilars enter
- Regulatory support and payer incentives facilitate adoption
- Patent expirations will drive more biosimilar entries, intensifying competition
FAQ
1. When did HADLIMA launch in the U.S.?
HADLIMA was approved by the FDA in August 2021; commercial launches began shortly after approval.
2. What are the primary indications for HADLIMA?
HADLIMA is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
3. How does HADLIMA's price compare to Humira?
The biosimilar is priced approximately 15-20% lower than Humira, translating to significant savings for healthcare providers and payers.
4. What regulatory hurdles could affect HADLIMA’s market growth?
Patent litigations and regulatory delays in some markets remain hurdles; however, consistent FDA support reduces this risk in the U.S.
5. What is the long-term potential for HADLIMA?
Market expansion into new indications and geographic regions, alongside competitive biosimilar launches, positions HADLIMA for sustained growth into the late 2020s.
References
[1] IQVIA. (2023). Worldwide Medicine Sales Data.
[2] U.S. Food and Drug Administration. (2021). Approval Letter for HADLIMA.
[3] Sandoz. (2023). Hyrimoz Market Data.
[4] IQVIA. (2023). Biosimilar Market Report.
[5] Biologic Price Competition and Innovation Act (BPCIA). (2009). Public Law No. 111-148.
